(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 16.3% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.52%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.43%.
Adaptive Biotechnologies's revenue in 2026 is $252,754,000.On average, 10 Wall Street analysts forecast ADPT's revenue for 2026 to be $41,434,858,675, with the lowest ADPT revenue forecast at $38,256,369,461, and the highest ADPT revenue forecast at $43,601,177,693. On average, 9 Wall Street analysts forecast ADPT's revenue for 2027 to be $50,984,066,184, with the lowest ADPT revenue forecast at $46,962,865,133, and the highest ADPT revenue forecast at $56,360,934,106.
In 2028, ADPT is forecast to generate $60,751,584,913 in revenue, with the lowest revenue forecast at $57,151,739,780 and the highest revenue forecast at $64,007,933,373.